Zacks Investment Research on MSN

Sanofi's venglustat meets primary endpoints in Gaucher disease study

Sanofi SNY announced that a late-stage study, evaluating venglustat, an investigational oral glucosylceramide synthase inhibitor (GCSi), in patients aged 12 years and older with type 3 Gaucher disease ...
MPR

Venglustat Improves Neurological Symptoms in Type 3 Gaucher Disease

Findings from the LEAP2MONO study support the regulatory submission of venglustat for treatment of type 3 Gaucher disease.
Medscape

Noninvasive Spleen Test Predicts Liver Disease Complications

Spleen stiffness measurement (SSM) demonstrated strong predictive accuracy for liver decompensation in patients with compensated advanced chronic liver disease (cACLD), with an optimal cutoff of 50 ...
Healio

Incidentally detected splenomegaly may be risk factor for blood, liver cancers

Individuals with incidentally detected splenomegaly may be at increased risk for blood and liver cancers, as well as ...